Menu
Enrolling by invitation NCT07503847

Shared Decision-Making for Colorectal Cancer Screening in High-Risk First-Degree Relatives Aged 40-49

No phase Interventional Colo-rectal Cancer Shared Decision Making Patient Decision Aid

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Colonoscopy, Shared Decision-Making.
Who it may be relevant to
Registry conditions: Colo-rectal Cancer, Shared Decision Making, Patient Decision Aid. Basic parameters: 40 years — 49 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized Controlled Trial on Shared Decision-Making for Colorectal Cancer Screening Among High-Risk First-Degree Relatives Aged 40-49

Overview

The primary objective of this study was to evaluate the impact of a constructed shared decision (SDM) intervention (offering an option between colonoscopy and immunochemical collapsible occult blood testing (fecal immunochemical test; FIT)) on improving the incidence of high colonoscopy stromal in patients aged 40-49 years with a close relative suffering from colorectal cancer, compared to standard care (direct referral for colonoscopy).

Interventions

  • Diagnostic test Colonoscopy
    Participants underwent standard colonoscopy performed by experienced endoscopists following routine clinical procedures.
  • Behavioral Shared Decision-Making
    Participants received a shared decision-making intervention including educational materials and discussion with clinicians to choose between screening options.

Primary outcome measures

  • Colonoscopy screening rate [Time frame: Within 3 months after randomization]
Secondary outcome measures (3)
  • Patient satisfaction with shared decision-making [Time frame: Immediately after the SDM consultation visit]
  • Participant choice of screening modality (colonoscopy vs fecal immunochemical test) [Time frame: Immediately after the intervention]
  • Detection rate of colorectal neoplasia [Time frame: During colonoscopy procedure]

Eligibility criteria

Inclusion criteria

  • Age 40 to 49 years at the time of recruitment.
  • At least one immediate family member (biological parent, sibling, or child) has been pathologically diagnosed with colorectal cancer.
  • Able to read, understand, and provide prior consent.
  • Willing to be randomly assigned to any research group and complete all research procedures.

Exclusion criteria

  • A personal history of colorectal cancer or inflammatory bowel disease (Crohn's disease or ulcerative colitis).
  • Presence of warning signs of colorectal cancer requiring diagnostic evaluation rather than screening (e.g., unexplained rectal bleeding, significant involuntary weight loss, persistent changes in bowel habits).
  • Presence of comorbidities that may contraindicate colonoscopy.
  • Having undergone colonoscopy within the past three years.
  • Inability to read, understand, and provide written informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Screening

Study locations

Taiwan · 1 center
  • National Taiwan University Hospital — Taipei

Identifiers

NCT: NCT07503847 · 202509053RINA

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗